Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110


Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study.

Betticher DC, Hsu Schmitz SF, Tötsch M, Hansen E, Joss C, von Briel C, Schmid RA, Pless M, Habicht J, Roth AD, Spiliopoulos A, Stahel R, Weder W, Stupp R, Egli F, Furrer M, Honegger H, Wernli M, Cerny T, Ris HB; Swiss Group for Clinical Cancer Research (SAKK).

Br J Cancer. 2006 Apr 24;94(8):1099-106.


Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial.

Betticher DC, Hsu Schmitz SF, Tötsch M, Hansen E, Joss C, von Briel C, Schmid RA, Pless M, Habicht J, Roth AD, Spiliopoulos A, Stahel R, Weder W, Stupp R, Egli F, Furrer M, Honegger H, Wernli M, Cerny T, Ris HB.

J Clin Oncol. 2003 May 1;21(9):1752-9.


Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935.

Kumar P, Herndon J 2nd, Langer M, Kohman LJ, Elias AD, Kass FC, Eaton WL, Seagren SL, Green MR, Sugarbaker DJ.

Cancer. 1996 Jun 1;77(11):2393-9.


Neoadjuvant therapy for surgically staged IIIA N2 non-small cell lung cancer (NSCLC).

Elias AD, Skarin AT, Leong T, Mentzer S, Strauss G, Lynch T, Shulman L, Jacobs C, Abner A, Baldini EH, Frei E 3rd, Sugarbaker DJ.

Lung Cancer. 1997 May;17(1):147-61.


Postoperative adjuvant chemotherapy and radiotherapy for stage II and III non-small cell lung cancer (NSCLC).

Lee SW, Choi EK, Chung WK, Shin KH, Ahn SD, Kim JH, Kim SW, Suh C, Lee JS, Kim WS, Kim DS, Kim DK, Park SI, Sohn KH.

Lung Cancer. 2002 Jul;37(1):65-71.


Long-term survival associated with complete resection after induction chemotherapy in stage IIIA (N2) and IIIB (T4N0-1) non small-cell lung cancer patients: the Spanish Lung Cancer Group Trial 9901.

Garrido P, González-Larriba JL, Insa A, Provencio M, Torres A, Isla D, Sanchez JM, Cardenal F, Domine M, Barcelo JR, Tarrazona V, Varela A, Aguilo R, Astudillo J, Muguruza I, Artal A, Hernando-Trancho F, Massuti B, Sanchez-Ronco M, Rosell R.

J Clin Oncol. 2007 Oct 20;25(30):4736-42.


Comparison of efficacy for postoperative chemotherapy and concurrent radiochemotherapy in patients with IIIA-pN2 non-small cell lung cancer: an early closed randomized controlled trial.

Shen WY, Ji J, Zuo YS, Pu J, Xu YM, Zong CD, Tao GZ, Chen XF, Ji FZ, Zhou XL, Han JH, Wang CS, Yi JG, Su XL, Zhu WG.

Radiother Oncol. 2014 Jan;110(1):120-5. doi: 10.1016/j.radonc.2013.10.008. Epub 2013 Oct 31.


Adjuvant chemotherapy for early-stage non-small-cell lung cancer. Single-centre experience and literature review.

Custodio Carretero AB, García Sáenz JA, González Larriba JL, Bobokova J, Calles Blanco A, Hernando Trancho F, García Paredes B, Rodríguez Lajusticia L, Díaz-Rubio García E.

Clin Transl Oncol. 2008 Sep;10(9):560-71.


Pre-operative chemoradiotherapy in non-small cell lung cancer stage III patients. Feasibility, toxicity and long-term results of a phase II study.

Favaretto A, Paccagnella A, Tomio L, Sartori F, Cipriani A, Zuin R, Reffosco L, Calabro F, Rea F, Ghiotto C, Chiarion-Sileni V, Oniga F, Loreggian L, Fiorentino MV.

Eur J Cancer. 1996 Nov;32A(12):2064-9.


Two commonly used neoadjuvant chemoradiotherapy regimens for locally advanced stage III non-small cell lung carcinoma: long-term results and associations with pathologic response.

Machtay M, Lee JH, Stevenson JP, Shrager JB, Algazy KM, Treat J, Kaiser LR.

J Thorac Cardiovasc Surg. 2004 Jan;127(1):108-13.


Accelerated induction therapy and resection for poor prognosis stage III non-small cell lung cancer.

Rice TW, Adelstein DJ, Koka A, Tefft M, Kirby TJ, Van Kirk MA, Taylor ME, Olencki TE, Peereboom D, Budd GT.

Ann Thorac Surg. 1995 Sep;60(3):586-91; discussion 591-2.


Surgery after induction chemotherapy in stage IIIA-N2 non-small cell lung cancer: why pneumonectomy should be avoided.

Kappers I, van Sandick JW, Burgers SA, Belderbos JS, van Zandwijk N, Klomp HM.

Lung Cancer. 2010 May;68(2):222-7. doi: 10.1016/j.lungcan.2009.07.001. Epub 2009 Aug 6.


Advantage of post-operative oral administration of UFT (tegafur and uracil) for completely resected p-stage I-IIIa non-small cell lung cancer (NSCLC).

Tanaka F, Miyahara R, Ohtake Y, Yanagihara K, Fukuse T, Hitomi S, Wada H.

Eur J Cardiothorac Surg. 1998 Sep;14(3):256-62; discussion 263-4.


Induction chemotherapy with triweekly docetaxel and cisplatin followed by concomitant chemoradiotherapy with or without surgery in stage III non-small-cell lung cancer: a phase II study.

Aydiner A, Sen F, Saglam EK, Oral EN, Eralp Y, Tas F, Toker A, Dilege S.

Clin Lung Cancer. 2011 Sep;12(5):286-92. doi: 10.1016/j.cllc.2011.03.030. Epub 2011 May 8.


Concomitant chemoradiotherapy with cisplatin and docetaxel followed by surgery and consolidation chemotherapy in patients with unresectable locally advanced non-small cell lung cancer.

Kaya AO, Buyukberber S, Benekli M, Coskun U, Sevinc A, Akmansu M, Yildiz R, Ozturk B, Yaman E, Kalender ME, Orhan O, Yamac D, Uner A; Anatolian Society of Medical Oncology (ASMO).

Med Oncol. 2010 Mar;27(1):152-7. doi: 10.1007/s12032-009-9186-z. Epub 2009 Feb 26.


Recurrence-free survival and prognostic factors in resected pN2 non-small cell lung cancer.

Choi YS, Shim YM, Kim J, Kim K.

Eur J Cardiothorac Surg. 2002 Nov;22(5):695-700.


Surgical multimodality treatment for baseline resectable stage IIIA-N2 non-small cell lung cancer. Degree of mediastinal lymph node involvement and impact on survival.

Decaluwé H, De Leyn P, Vansteenkiste J, Dooms C, Van Raemdonck D, Nafteux P, Coosemans W, Lerut T.

Eur J Cardiothorac Surg. 2009 Sep;36(3):433-9. doi: 10.1016/j.ejcts.2009.04.013. Epub 2009 Jun 6.


Weekly docetaxel and cisplatin with concomitant radiotherapy in addition to surgery and/or consolidation chemotherapy in stage III non-small cell lung cancer.

Sen F, Saglam EK, Toker A, Dilege S, Kizir A, Oral EN, Saip P, Sakallioglu B, Topuz E, Aydiner A.

Cancer Chemother Pharmacol. 2011 Dec;68(6):1497-505. doi: 10.1007/s00280-011-1642-8. Epub 2011 Apr 17.


Alternating radiotherapy and chemotherapy for inoperable Stage III non-small-cell lung cancer: long-term results of two Phase II GOTHA trials. Groupe d'Oncologie Thoracique Alpine.

Mirimanoff RO, Moro D, Bolla M, Michel G, Brambilla C, Mermillod B, Miralbell R, Alberto P.

Int J Radiat Oncol Biol Phys. 1998 Oct 1;42(3):487-94.


Phase II study of three-dimensional conformal radiotherapy and concurrent mitomycin-C, vinblastine, and cisplatin chemotherapy for Stage III locally advanced, unresectable, non-small-cell lung cancer.

Lee SW, Choi EK, Lee JS, Lee SD, Suh C, Kim SW, Kim WS, Ahn SD, Yi BY, Kim JH, Noh YJ, Kim SS, Koh Y, Kim DS, Kim WD.

Int J Radiat Oncol Biol Phys. 2003 Jul 15;56(4):996-1004.


Supplemental Content

Support Center